624 related articles for article (PubMed ID: 29866156)
1. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
[TBL] [Abstract][Full Text] [Related]
2. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Melisi D; Oh DY; Hollebecque A; Calvo E; Varghese A; Borazanci E; Macarulla T; Merz V; Zecchetto C; Zhao Y; Gueorguieva I; Man M; Gandhi L; Estrem ST; Benhadji KA; Lanasa MC; Avsar E; Guba SC; Garcia-Carbonero R
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688022
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
5. Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.
Hammad S; Cavalcanti E; Werle J; Caruso ML; Dropmann A; Ignazzi A; Ebert MP; Dooley S; Giannelli G
Arch Toxicol; 2018 Jul; 92(7):2297-2309. PubMed ID: 29808285
[TBL] [Abstract][Full Text] [Related]
6. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
Zhao F; Evans K; Xiao C; DeVito N; Theivanthiran B; Holtzhausen A; Siska PJ; Blobe GC; Hanks BA
Cancer Immunol Res; 2018 Dec; 6(12):1459-1471. PubMed ID: 30209062
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
8. Lingual Denervation Improves the Efficacy of Anti-PD-1 Immunotherapy in Oral Squamous Cell Carcinomas by Downregulating TGFβ Signaling.
Tao ZY; Wang L; Zhu WY; Zhang G; Su YX
Cancer Res Commun; 2024 Feb; 4(2):418-430. PubMed ID: 38324026
[TBL] [Abstract][Full Text] [Related]
9. Photothermal therapy mediated by gold nanocages composed of anti-PDL1 and galunisertib for improved synergistic immunotherapy in colorectal cancer.
Wang S; Song Y; Cao K; Zhang L; Fang X; Chen F; Feng S; Yan F
Acta Biomater; 2021 Oct; 134():621-632. PubMed ID: 34329782
[TBL] [Abstract][Full Text] [Related]
10. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
[TBL] [Abstract][Full Text] [Related]
11. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
[TBL] [Abstract][Full Text] [Related]
12. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
[TBL] [Abstract][Full Text] [Related]
13. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
14. Galunisertib enhances chimeric antigen receptor-modified T cell function.
Wang Z; Liu Q; Risu N; Fu J; Zou Y; Tang J; Li L; Liu H; Zhou G; Zhu X
Eur J Histochem; 2020 Jun; 64(s2):. PubMed ID: 32705856
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
17. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Yingling JM; McMillen WT; Yan L; Huang H; Sawyer JS; Graff J; Clawson DK; Britt KS; Anderson BD; Beight DW; Desaiah D; Lahn MM; Benhadji KA; Lallena MJ; Holmgaard RB; Xu X; Zhang F; Manro JR; Iversen PW; Iyer CV; Brekken RA; Kalos MD; Driscoll KE
Oncotarget; 2018 Jan; 9(6):6659-6677. PubMed ID: 29467918
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.
Sheng W; Liu Y; Chakraborty D; Debo B; Shi Y
Cancer Discov; 2021 Aug; 11(8):1970-1981. PubMed ID: 33687985
[TBL] [Abstract][Full Text] [Related]
19. Promotion of liver regeneration and anti‑fibrotic effects of the TGF‑β receptor kinase inhibitor galunisertib in CCl4‑treated mice.
Masuda A; Nakamura T; Abe M; Iwamoto H; Sakaue T; Tanaka T; Suzuki H; Koga H; Torimura T
Int J Mol Med; 2020 Jul; 46(1):427-438. PubMed ID: 32377696
[TBL] [Abstract][Full Text] [Related]
20. Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy.
Ludwig N; Wieteska Ł; Hinck CS; Yerneni SS; Azambuja JH; Bauer RJ; Reichert TE; Hinck AP; Whiteside TL
Mol Cancer Ther; 2021 Jun; 20(6):1102-1111. PubMed ID: 33850003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
